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Introduction: Trimodality therapy (TMT), consisting of extrapleu-
ral pneumonectomy (EPP), preoperative or postoperative combina-
tion chemotherapy, and high-dose hemithoracic radiotherapy, is the
only therapy reported to achieve long-term survival in selected
patients with malignant pleural mesothelioma (MPM). Thus, TMT
was introduced as an option for such patients in Western Australia
in 2004. However, TMT has never been compared with non-TMT
therapy in the same patient population, thereby introducing a poten-
tial for selection bias.
Method: We performed a retrospective review of all patients re-
ferred for TMT consisting of EPP, adjuvant chemotherapy, and
hemithoracic radiotherapy at a quaternary referral institution. Patient
eligibility for referral for TMT was based on patients’ tolerability for
pneumonectomy, epithelioid subtype, and computed tomography
and positron emission tomography scanning indicating operable
disease, with the exclusion of extrapleural lymphadenopathy and
metastatic disease (clinical stage T1-3N0-1M0). Eligible patients
consenting to TMT also underwent a surgical staging procedure
(bilateral thoracoscopy, mediastinoscopy, and laparoscopy) to con-
firm eligibility before EPP.
Results: Thirty-six patients have been referred for TMT since 2004,
and there has been a median of 27 months follow-up; of 31 patients
having surgical staging, eight were ineligible for EPP and one
declined EPP. Of the 22 planned for EPP, 18 underwent EPP and
four had unresectable disease at surgery. There was one death in
hospital six days post-EPP and another death postdischarge and 28
days post-EPP (30-day mortality 11%); 15 of 16 EPP survivors
received adjuvant chemotherapy and 14 completed adjuvant radio-
therapy. Pathologic analysis of the 18 resected EPP specimens
revealed N2 disease in seven patients (39%) and nonepithelioid
subtype in six patients (33%). Local recurrence did not occur among
EPP survivors; however, 56% (9 of 16 patients) developed distant
recurrence. Median and 1-year survival did not differ between the 18
EPP patients and 18 non-EPP patients (20.4 versus 20.7 months and
76 versus 78%, respectively; p  NS).
Discussion: In this case series, we could not demonstrate a survival
benefit for patients in the EPP group compared with that in the
non-EPP group. After surgical staging, 26% of patients were ineli-
gible for TMT. Thus, surgical staging is essential before proceeding
with EPP. Despite aggressive imaging and surgical staging, 39% of
patients will have N2 disease and 18% will have unresectable
disease at operation. Although complete locoregional control was
achieved with TMT, distant recurrence affected most EPP survivors
despite careful patient selection and a high rate of completion of
adjuvant therapy. We conclude that TMT for operable epithelioid
MPM requires further assessment in randomized controlled trials.
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Malignant pleural mesothelioma (MPM) has a poor prog-nosis, with reported median survivals of 6 to 12
months; a minority of patients respond to combination che-
motherapy, which results in an improved median survival of
a few months overall.1 Trimodality therapy (TMT), consist-
ing of extrapleural pneumonectomy (EPP), neoadjuvant or
adjuvant chemotherapy, and adjuvant high-dose hemithoracic
radiotherapy, has been reported to offer long-term survival in
selected patients with MPM.2 However, TMT outcomes have
never been reported compared with non-TMT therapy in
similar patients otherwise suitable for EPP; thus, the potential
for selection bias in published surgical series exists,3 and the
role of TMT for MPM is unclear. The main foundation for the
hypothesis of improved survival with TMT rests with a large
case series collated more than 17 years in 183 selected
patients undergoing TMT in whom there was a perioperative
mortality of 3.8%, and in the remaining patients, there was a
median survival of 19 months.2 In a subgroup of 31 patients
with epithelioid histology, negative extrapleural nodes, and
negative resection margins, there was a 46% 5-year survival
and a median survival of 51 months.2 Other recent series have
reported median survivals ranging from 15 to 25 months.4–8
However, there have not been any randomized controlled
trials to assess this approach, although one is currently being
carried out.3,9
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TMT represents a significant undertaking for patients
and treatment for a prolonged period of time (i.e., 24 weeks
or more) for a disease with limited survival time. The need to
target TMT only at those with features anticipating improved
survival is axiomatic. We hypothesized that in presumed
early-stage mesothelioma, multifocal mesothelioma (i.e.,
N2-3 or M1 disease) was possible and unable to be detected
by contemporary imaging modalities (i.e., computed tomog-
raphy [CT], magnetic resonance imaging, and positron emis-
sion tomography [PET]).10 We have reported that the assess-
ment for occult disease in the contralateral chest, abdomen,
and mediastinum by endoscopic means (i.e., surgical staging)
is essential before proceeding with EPP, because 26% of our
patients were found to have more extensive disease than
anticipated, precluding resection.11 Furthermore, patients
identified by surgical staging to be positive for occult meta-
static disease had a poor prognosis, with 55% dying from
mesothelioma by 1 year.11 Although upstaging of mesotheli-
oma has been reported by the use of these endoscopic
procedures, no other group to date has routinely used all of
bilateral thoracoscopy, laparoscopy, and mediastinoscopy in
this way.12–15
The state of Western Australia has one of the highest
incidences of MPM in the world, because of the mining of
crocidolite asbestos in the town of Wittenoom from 1943 to
1966.16 In the 3 years from 2004 to 2006, there were 246
cases of MPM diagnosed in Western Australia.17 Since 2004,
one surgeon in Western Australia, a state with a population of
approximately 2 million people, has offered EPP as part of
TMT for selected patients with early epithelioid MPM. We
reviewed our experience in patients with epithelioid MPM
deemed operable after imaging and multidisciplinary review,
and who were referred for consideration of EPP. Our objec-
tive was to assess the outcomes of all patients referred for
consideration of EPP, including survival outcomes according
to whether EPP was performed, and to assess patterns of
recurrence in patients treated by EPP.
PATIENTS AND METHODS
Data from eligible patients referred for TMT between
the start of the service in June 2004 and April 2007 were
collected prospectively. Patient notes were reviewed retro-
spectively for information relating to presentation, diagnosis,
investigations, and treatment. Wherever possible, all radiologic
investigations and histopathologic samples were reviewed. Date
of diagnosis was defined as the date that cytologic or histopatho-
logic specimens were first reported as MPM.
Eligibility criteria have been published previously.11
Briefly, eligible patients were those with untreated epithelioid
MPM that was surgically resectable on the basis of CT,
magnetic resonance imaging, and PET evaluation and were
eligible to undergo EPP (as per British Thoracic Society
guidelines).11,18 Previous pleural drainage was allowed but
not pleurodesis. Surgical resectability was defined as disease
that was completely resectable with no subdiaphragmatic
disease, no extrapleural nodal involvement, and no distant
disease (clinical stage T1-3N0-1M0). Patients with sarcoma-
toid or biphasic MPM (10% sarcomatoid component) iden-
tified before referral were ineligible for TMT. Patients were
required to have an adequate cardiac, renal, and hepatic organ
function and a predicted postoperative FEV1 of more than 1
L. Analysis was performed with follow-up to April 1, 2008.
Surgical Staging and Management
A flow chart summarizing planned investigations and
management is shown in Figure 1. All cases were reviewed
initially at a multidisciplinary meeting by a respiratory phy-
sician, radiologist, pathologist, nuclear physician, radiation
and medical oncologists, and cardiothoracic surgeon to con-
firm suitability for referral. At the initial outpatient visit, the
surgeon would discuss the rationale and current knowledge
base for TMT. If the patient agreed to proceed, a staging
operation consisting of bilateral thoracoscopy, mediastinos-
copy, and laparoscopy was performed using techniques de-
scribed previously.11 Biopsies of macroscopically abnormal
tissue were taken; in addition, multiple random biopsies were
FIGURE 1. Flow chart of workup and treatment of eligible
patients referred for TMT. MDM, multidisciplinary meeting;
MPM, malignant pleural mesothelioma; TMT, trimodality
therapy; EPP, extrapleural pneumonectomy.
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taken from sites of macroscopically normal tissue to detect
occult disease in the contralateral hemithorax and subdia-
phragmatic peritoneum.
If surgical staging confirmed resectable epithelioid
MPM, the patient was offered the option to proceed to EPP
using techniques described previously.19 This was followed
by three cycles of adjuvant chemotherapy starting 6 to 8
weeks postoperatively. Until 2005, adjuvant chemotherapy
consisted of cisplatin and gemcitabine.20 In 2005, pemetrexed
became available for MPM in Western Australia, and since then
cisplatin and pemetrexed chemotherapy have been used.1
Ipsilateral hemithoracic irradiation was planned to start
6 weeks after day 1 of the last cycle of chemotherapy. All
patients had CT treatment planning. External beam radiother-
apy was delivered with 6 MV photons using opposed anterior
and posterior fields. The total radiation dose prescribed to the
thorax was 54 Gy in 30 fractions of 1.8 Gy per fraction, with
treatments each weekday. The fields were reduced off the
spinal cord after 39.6 Gy had been delivered in 22 fractions.
Anterior and posterior blocks were used throughout to shield
the ipsilateral kidney and part of the liver or stomach, with
appropriate energy electrons of 12 to 20 MeV selected to treat
the blocked areas. For left-sided tumors, anterior heart shield-
ing was used after 19.8 Gy, with the remaining treatment
delivered with electrons. Patients were said to have com-
pleted TMT if they received all three cycles of adjuvant
chemotherapy and received all 30 fractions of adjuvant ra-
diotherapy. Patients were followed up with 3 monthly clinical
review and 6 monthly CT scan of the thorax and abdomen.
Statistical Methods
Statistical analysis was performed using SPSS 13.0
package (SPSS Inc, Chicago, IL). Statistical comparisons for
survival were made using the log-rank test between those
patients who underwent EPP (EPP patients) and those who
did not, for any reason, undergo EPP (non-EPP patients). The
EPP group included those who did not complete TMT and
those who did not survive the perioperative period.
RESULTS
After multidisciplinary evaluation, 36 patients were
referred for TMT (Table 1). The median follow-up was 27.6
months from diagnosis. Most patients presented with chest
pain (50%) and/or dyspnea (67%). Three cases were found
incidentally on imaging, two on surveillance carried out to
follow-up residents of a former asbestos-mining community.
There was a significantly longer time between presentation and
the diagnosis of MPM for the non-EPP group compared with
that for the EPP group (42 days versus 22 days, p  0.04).
The progression through staging and management of
the 36 patients is shown in Figure 2. Thirty-one of 36 patients
underwent surgical staging procedures. Of the remaining five
patients, three declined to proceed to surgical staging, one
was diagnosed with sarcomatoid subtype on biopsies taken
during a separate therapeutic thoracoscopic procedure, and
one patient in the interim of assessment had a radical pleu-
rectomy by another surgeon in the mistaken belief that EPP
would still be possible.
Surgical Staging
Of the 31 patients who underwent surgical staging, 22
patients were found to be suitable for EPP and booked to have
EPP. Of the nine patients who did not proceed to EPP, one
was suitable but declined and sought alternative therapy. Six
patients were found to have inoperable disease after being
upstaged on the basis of findings from the staging operation:
two with mediastinal invasion as determined by mediastinos-
copy and confirmed on biopsy; two with subdiaphragmatic
disease confirmed with biopsy during laparascopy; one with
both subdiaphragmatic disease detected on laparoscopy and
sarcomatoid subtype in the ipsilateral pleura and abdomen;
and one with subdiaphragmatic disease and disease in the
contralateral chest, with the disease in the contralateral chest
only being discovered on random biopsy of macroscopically
normal pleura. One patient was not upstaged but had biopsies
taken during the surgical staging procedure that showed
sarcomatoid subtype. The remaining patient was assessed as
physiologically unfit for EPP based on difficulty recovering
from the staging procedure. Hence, eight of the 31 patients
(26%) undergoing surgical staging had the decision to have
EPP directly affected by the surgical staging procedure and
did not proceed to EPP. The surgical staging procedure was
well tolerated with a median length of stay in hospital of 3
days (range 1–10 days), with no major complication or
mortality.
Extrapleural Pneumonectomy
Of the 22 patients booked for EPP, four were found to
have locally advanced disease intraoperatively: two patients
had extensive pericardial seeding; one had involvement of the
aorta; and one had esophageal involvement extending across
the midline. Without the possibility of complete resection of
all macroscopic disease, these four patients had other proce-
TABLE 1. Characteristics at Presentation of Patients
Referred for TMT
Total
(n  36)
EPP
(n  18)
Non-EPP
(n  18)
Age at diagnosis (yr) mediana
(range)
60 (40–72) 57 (40–69) 64 (42–72)
Sex
Male 30 15 15
Female 6 3 3
Side of MPM
Left 19 10 9
Right 17 8 9
Presentation
Symptomatic 33 18 15
Incidental 3 0 3
Smoking status
Never 17 7 10
Former 19 11 8
a p  0.04 for EPP versus non-EPP group.
TMT, trimodality therapy; MPM, malignant pleural mesothelioma; EPP, extrapleu-
ral pneumonectomy.
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dures at the time such as pleurectomy and talc pleurodesis
with or without pericardectomy.
The remaining 18 patients underwent EPP. There was
one perioperative death 6 days after an uneventful operation
from iatrogenic pulmonary edema, likely associated with
epidural analgesia; another patient after an uneventful oper-
ation also developed a fatal pulmonary embolism, 28 days
after discharge. All patients before discharge had Doppler
venous surveillance, and all were negative for deep vein
thrombosis. Thus, the total perioperative mortality rate was
11%. The median length of hospital stay for the patients
undergoing EPP was 13 days (range 7–21 days), excluding
the death at 6 days. Patients were successfully managed for
postoperative complications including mild acute renal fail-
ure (n  1) and deep vein thrombosis (n  1). All patients
required blood transfusions, and there were no cases of major
bleeding, empyema, or bronchopleural fistula.
Staging details are shown in Table 2. Staging on im-
aging criteria alone was similar between the two groups;
however, it is important to note that, by definition, patients in
the EPP/TMT group were more rigorously staged because
non-TMT patients could be excluded from further staging
procedures at any point along the pathway when inoperable
disease was demonstrated or for other medical and personal
reasons.
On detailed histologic examination (30 slices), all EPP
specimens were found to have at least one positive resection
margin. The tumors were predominantly epithelioid, although
six cases were found to have sarcomatoid foci in the resected
tumor. Seven patients had extrapleural nodal involvement
beyond the reach of previous staging mediastinoscopy—these
were paraesophageal and paraaortic nodes—and in half of
cases the involved nodes were less than 10 mm.
Adjuvant Therapy
One patient recovered poorly from EPP, largely as a
result of depression, and did not receive any of the planned
adjuvant chemotherapy or radiotherapy. All of the remaining
15 patients received adjuvant treatment. There was a median
of 9 weeks between EPP and the start of adjuvant chemo-
therapy (range 6–11 weeks). In combination with cisplatin,
five patients received gemcitabine and 10 patients received
pemetrexed. One patient received only two of three planned
cycles because of nausea/vomiting. There were no treatment-
related deaths, but three patients required dose reduction for
nausea/vomiting and/or fluid retention, and two of these three
patients were admitted to hospital because of these treatment-
related toxicities. One patient was diagnosed with asymptom-
atic pulmonary embolism after completing chemotherapy and
before starting radiotherapy.
There was a median of 30 days between the last day of
chemotherapy administration and the start of radiotherapy.
All 15 patients who received adjuvant chemotherapy subse-
TABLE 2. IMIG Stage Based on Imaging and Surgical
Staging
IMIG
Stage21
EPP
(n  18)
Non-EPP
(No. Patients)
Imaging I 5 7
II 8 6
III 5 5
Surgical staging I 5 0
II 9 5
III 4 2
IV 0 6
IMIG, International Mesothelioma Interest Group; EPP, extrapleural pneumonectomy.
FIGURE 2. Flow chart of patient progression. TMT, trimo-
dality therapy; EPP, extrapleural pneumonectomy.
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quently started radiotherapy and 14 completed it. One patient
who had N2 disease and focal sarcomatoid pathology on the
EPP specimen was diagnosed with distant recurrence during
adjuvant radiotherapy. Radiotherapy was well tolerated with
predictable grade 2 toxicities including oesophagitis and skin
erythema, and no grade 3/4 side effects were reported. Over-
all, 72% (13 of 18) of those who underwent EPP completed
all components of TMT.
Of the 18 non-EPP patients, 14 received palliative
chemotherapy (five of these had a pleurectomy), two pursued
alternative therapies, and two received supportive care only.
Survival
Kaplan-Meier survival curves from date of diagnosis
for the 18 EPP patients and 18 non-EPP patients are shown in
Figure 3. The median survival postdiagnosis for the EPP
group was 20.7 months, with a 1-year survival of 76%.
Median survival from the date of EPP was 19 months (range
6 days–41 months). Median survival from the date of EPP for
the six patients with positive N2 nodes who survived the
perioperative period (12.6 months) and the 10 patients with
negative N2 nodes (19 months) was not statistically signifi-
cantly different, although patient numbers were small. Four
patients in the EPP group have lived more than 2 years since
diagnosis. Two of these four had positive N2 nodes, and three
of these four have CT detectable recurrent disease. The
longest survivor in the EPP group has lived 46 months since
diagnosis and remains free of disease clinically and on
imaging.
The median survival postdiagnosis for the non-EPP
group was 20.4 months, with a 1-year survival of 78%. Five
patients in the non-EPP group have survived for more than 2
years since diagnosis; there are currently no 3-year survivors
in this group. For the patients in the non-EPP group who had
an incidental diagnosis of MPM, the survival postdiagnosis
was 15 months for two patients and 7 months for the remain-
ing patient. For the six patients excluded from EPP because
of upstaging from the surgical staging operation, the median
survival postdiagnosis was 8 months, with a 1-year survival
of 50%.
Patterns of Recurrence
Table 3 provides details on the nine patients (56%) who
have been diagnosed with disease recurrence post-EPP. There
were no local recurrences. The median disease-free survival
for all EPP patients was 12.5 months, and most of the patients
who recurred within 12 months of EPP had multiple high-risk
features on the resected histopathologic specimen. Three
recurrences have occurred in the contralateral chest only, and
two of these were asymptomatic and detected on routine
follow-up imaging. Three patients had exclusively intraab-
dominal disease recurrence, presenting with ascites and un-
dergoing rapid clinical deterioration. Three patients have had
recurrent disease in multiple sites and also deteriorated
quickly. Abdominal recurrences were characterized by early
presentation, rapid clinical deterioration, and inadequate per-
formance status for second-line chemotherapy. Those with
FIGURE 3. Kaplan-Meier survival curves of survival after
date of diagnosis for EPP group (n  18) and non-EPP group
(n  18). EPP, extrapleural pneumonectomy.
TABLE 3. Details of Disease Recurrence Post-EPP
Patient
High-Risk Histopathalogic Features
on EPP Specimen
Diagnosis of
Recurrence
(mo post-EPP) Sites of Recurrence
Further
Treatment
Status at
Analysis
Survival after
Recurrence (mo)
1 Focal sarcomatoid, positive margin, and
N2 disease
5.5 Ascites, liver, contralateral pleural
effusion
No Deceased 0.7
2 Focal sarcomatoid, positive margin, and
N2 disease
9 Ascites/peritoneum No Deceased 0.5
3 Positive margins 11 Ascites/peritoneum No Deceased 1.8
4 Biphasic, positive margins, and
N2 disease
11.5 Ascites/peritoneum Yes Deceased 6.7
5 Biphasic, positive margin 12 Contralateral lung, liver, bone,
mesentery
Yes Deceased 5.5
6 Positive margins 16 Contralateral lung No Deceased 3.3
7 Positive margins 23 Contralateral lung Yes Alive 10.5
8 Positive margins 25 Contralateral lung Yes Deceased 4.7
9 Positive margins, N2 disease 37.5 Ascites, contralateral lung Yes Alive 1
EPP, extrapleural pneumonectomy.
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recurrence in the contralateral chest only were generally
diagnosed later and were usually able to receive further
chemotherapy.
DISCUSSION
We report for the first time the survival of all patients
referred for consideration of EPP by an experienced multi-
disciplinary team, after appropriate imaging evaluation and
pathologic diagnosis. We have demonstrated that in no pa-
tient is it possible to achieve a complete resection (i.e., R 
0) after examination of 30 histologic sections and that despite
thorough imaging and surgical staging workup, 18% of pa-
tients have locally advanced inoperable disease, 39% of
resected specimens demonstrated N2 disease, and 33% of
resected tumors exhibit sarcomatous foci.
In this series, the median and 1-year survivals for the
EPP group are comparable with those in most reported TMT
case series. However, the median and 1-year survival were
similar for the group undergoing EPP and those who were
referred and considered for EPP but did not undergo the proce-
dure for any reason. This is despite many patients in the non-
EPP group having more advanced disease, sarcomatoid sub-
type, or other physiological factors, which rendered them
unsuitable for EPP. Of note, we analyzed survival for all
patients who underwent EPP, not just those who survived EPP
or completed TMT. In advising patients preoperatively, a con-
sideration of the outcome for all patients gives a more secure
basis for decision making. Importantly, the prognosis of these
select patients with MPM is not as dismal as is often reported.
We acknowledge that our patient numbers are small,
but that other case series reporting on outcomes of TMT in
MPM have reported on similar numbers of patients undergo-
ing EPP, and the only randomized trial assessing TMT in
MPM, the Mesothelioma and Radical Surgery Trial study,
has only randomized 45 patients from 11 centers over 3
years.4,6,22 Also, our non-EPP group was heterogeneous in
disease extent, treatment received, and reasons for not under-
going EPP. Although the non-EPP group had a relatively
good survival compared with that in other patients with
MPM, it is likely that patients considered for EPP, whether
they undergo the procedure or not, have a better prognosis
than patients with MPM as a whole. This case series high-
lights the potential for selection bias in a series reporting only
those patients undergoing this form of surgical management
and underscores the need for properly designed, large, ran-
domized controlled trials of TMT in MPM.3,9
A unique strength of our study is that all patients were
uniformly assessed, staged, and managed by an experienced
multidisciplinary team including one cardiothoracic surgeon
and a number of medical and radiation oncologists in a
geographically isolated center with a high incidence of me-
sothelioma. Patient selection criteria for EPP were decided by
the team prospectively and were informed by previous reports
suggesting that epithelioid subtype, negative extrapleural
nodes, and potential for complete resection are important.
Chemotherapy was given postoperatively rather than preop-
eratively, although practices varied worldwide. There is no
clear clinical trial evidence to support one approach over the
other, and our practice followed that of Sugarbaker et al.2
Furthermore, those researchers who have reported on preop-
erative chemotherapy reported a very high complication rate
of postpneumonectomy empyema and bronchopleural fistu-
lae.23 We acknowledge that the timing of chemotherapy
remains an open question and that the advantages of neoad-
juvant chemotherapy may include downstaging and identifi-
cation of rapidly progressing and chemoresistant disease.
We have demonstrated that EPP is inappropriate for as
many as 26% of patients with apparently operable epitheliod
MPM on CT and PET imaging. This was most commonly
because of upstaging or diagnosis of sarcomatoid subtype
after careful surgical staging. As far as we are aware, our
series is unique relating to TMT for MPM, because we have
routinely staged patients with each of bilateral thoracoscopy,
laparoscopy, and mediastinoscopy, and these findings suggest
that a significant proportion of patients would be excluded
from TMT if thorough surgical staging were performed
routinely. We, thus, recommend these procedures to include
biopsies of macroscopically abnormal tissue and random
biopsies of apparently normal areas if TMT is to be consid-
ered. Exclusion of patients from TMT based on histologic
subtype is controversial, however, and other institutions have
different policies regarding this.5
We are also the first to report that it is not technically
possible to achieve negative resection margins (R  0). The
surgical plane of dissection for EPP is the endothoracic plane
of loose areolar connective tissue, which is not a barrier to
spread by mesothelioma. Previous reports of achieving com-
plete resection may well be limited by the number of slices
submitted for histologic analysis.
Furthermore, in a significant number (18%) of patients
despite surgical staging, it will not be possible to achieve
complete extirpation of the tumor. Two of our cases had
unexpected extensive pericardial seeding of MPM at the time
of the planned EPP. Also, N2 disease was present in 39% of
resected specimens despite mediastinoscopy, a figure similar
to other reported series and indicating a failure to detect N2
disease because of sampling error or inability to sample nodes
that are not reachable by mediastinoscopy.13
Despite aggressive surgical staging and adjuvant che-
motherapy and radiotherapy, most EPP patients surviving the
postoperative period developed distant recurrence. Patients
who had distant recurrence within a year of EPP had multiple
high-risk features on their EPP specimens that were not
detected preoperatively, such as areas of sarcomatoid histol-
ogy and N2 disease. Local thoracic control in our series was
complete, suggesting that surgical and radiation techniques were
adequate. However, distant recurrence remains a problem de-
spite a high completion rate (81%) of adjuvant chemotherapy. It
seems likely that current adjuvant systemic treatment is not able
to eliminate micrometastases, highlighting the need for im-
proved systemic treatments for mesothelioma. It is important to
note that the optimal timing, duration, and regimen of adjuvant
chemotherapy in this setting have not been established.
In summary, our case series has demonstrated that
patients who are initially deemed suitable for TMT may in
fact be a good prognostic group and that this selection, rather
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than TMT, may underlie the promising survival figures
shown in highly selected case series. Results of randomized,
controlled clinical trials such as the Mesothelioma and Radical
Surgery Trial study are awaited to further clarify the controversy
surrounding surgical management of MPM. We also show the
importance of surgical staging to exclude patients with adverse
prognostic features or unresectable disease who should not
undergo EPP. In any trial involving EPP, unless surgical
staging is performed, as many as 19% of patients will have a
lung removed with mesothelioma present in the extrapleural
nodes, contralateral chest, and/or abdomen. Furthermore, the
three criteria on which the foundation of TMT is based—
negative resection margins, negative extrapleural nodes, and
epitheliod histology—will, despite imaging and surgical stag-
ing, be incorrect in 100, 39, and 33% of patients, respectively.
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